Immunocore

Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.
Type
Private
HQ
Milton, GB
Employees
186 (est)+5%
Immunocore is headquartered in Milton, GB

Key People at Immunocore

Eliot Forster

Eliot Forster

CEO
Bent Jakobsen

Bent Jakobsen

Chief Scientific Officer
Eva-Lotta Allan

Eva-Lotta Allan

Chief Business Officer
Christina Coughlin

Christina Coughlin

Chief Medical Officer
Namir Hassan

Namir Hassan

Director of Translational Research & Development
Henrik Sorensen

Henrik Sorensen

Head of Alliance Management

Immunocore Locations

Milton, GB

Immunocore Metrics

Immunocore Summary

Total Funding

$320 M

Latest funding size

$320 M

Time since last funding

over 1 year

Investors

Immunocore's latest funding round of $320 M was in July 2015. In total, Immunocore has raised $320 M.

Immunocore Company Life

You may also be interested in